ClearBridge Investments
RYTM icon

ClearBridge Investments’s Rhythm Pharmaceuticals RYTM Stock Holding History

ClearBridge Investments’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$75.7M Buy
795,077
+98,604
+14% +$10.5M 0.07% 261
2026
Q2 		$77.3M Buy
696,473
+87,036
+14% +$7.87M 0.06% 261
2026
Q1 		$53M Buy
609,437
+103,328
+20% +$10M 0.05% 299
2025
Q4 		$54.2M Buy
506,109
+21,377
+4% +$2.27M 0.04% 313
2025
Q3 		$49M Buy
484,732
+172,287
+55% +$16M 0.04% 329
2025
Q2 		$19.7M Buy
+312,445
New +$19.1M 0.02% 418
2024
Q4 		– Sell
-87,424
Closed -$4.58M – 741
2024
Q3 		$4.58M Sell
87,424
-684
-0.8% -$32.8K ﹤0.01% 583
2024
Q2 		$3.62M Sell
88,108
-1,896
-2% -$75.7K ﹤0.01% 602
2024
Q1 		$3.9M Sell
90,004
-1,154
-1% -$50.5K ﹤0.01% 598
2023
Q4 		$4.19M Sell
91,158
-91,667
-50% -$2.89M ﹤0.01% 594
2023
Q3 		$4.19M Buy
+182,825
New +$4.09M ﹤0.01% 553
2020
Q3 		– Sell
-724
Closed -$16K – 952
2020
Q2 		$16K Hold
724
– – ﹤0.01% 863
2020
Q1 		$11K Sell
724
-24
-3% -$430 ﹤0.01% 941
2019
Q4 		$17K Hold
748
– – ﹤0.01% 973
2019
Q3 		$16K Sell
748
-30,047
-98% -$645K ﹤0.01% 961
2019
Q2 		$677K Hold
30,795
– – ﹤0.01% 680
2019
Q1 		$844K Buy
30,795
+3
+0% +$86 ﹤0.01% 687
2018
Q4 		$828K Sell
30,792
-15
-0% -$415 ﹤0.01% 700
2018
Q3 		$899K Sell
30,807
-47
-0.2% -$1.48K ﹤0.01% 732
2018
Q2 		$964K Sell
30,854
-7,410
-19% -$203K ﹤0.01% 650
2018
Q1 		$761K Buy
38,264
+36,476
+2,040% +$968K ﹤0.01% 653
2017
Q4 		$52K Buy
+1,788
New +$47.3K ﹤0.01% 845

Other funds holding RYTM

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Primecap Management
Primecap Management Pasadena, California $161B AUM 86.05% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 42.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $71.4B AUM 33.43% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

ClearBridge Investments's RYTM Position: Q3 2026 in Review

ClearBridge Investments increased its Rhythm Pharmaceuticals (RYTM) stake by 14% in Q3 2026, buying an estimated $10.5M and bringing the position to 795,077 shares worth $75.7M. The position accounts for 0.07% of the portfolio, ranked #261.

ClearBridge Investments first reported a position in RYTM in Q4 2017 and has held it in 22 quarters since. The position peaked at $77.3M in Q2 2026. 239 funds tracked by Wall St. Rank hold RYTM as of Q3 2026.

  • ClearBridge Investments held 795,077 shares of Rhythm Pharmaceuticals worth $75.7M as of Q3 2026.
  • ClearBridge Investments bought 98,604 Rhythm Pharmaceuticals shares in Q3 2026, an estimated $10.5M.
  • Rhythm Pharmaceuticals made up 0.07% of ClearBridge Investments's portfolio in Q3 2026, its #261 holding.
  • ClearBridge Investments first reported a position in Rhythm Pharmaceuticals in Q4 2017 and has held it in 22 quarters since.
  • ClearBridge Investments's Rhythm Pharmaceuticals position peaked at $77.3M in Q2 2026.
  • 239 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q3 2026.

Based on ClearBridge Investments's 13F filing for Q3 2026, filed 12 Nov 2026.